Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer. | Clin Cancer Res | 2022 | 34980602 | PubTator, text mining | PubMed |
| Profiling of immune features to predict immunotherapy efficacy. | Innovation (Camb) | 2022 | 34977836 | PubTator, text mining | PubMed |
| Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory. | Mol Cancer Ther | 2022 | 34965961 | PubTator, text mining | PubMed |
| Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases. | Biomed Pharmacother | 2022 | 34915673 | PubTator, text mining | PubMed |
| Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity. | Pharmacol Res | 2022 | 34915126 | PubTator, text mining | PubMed |
| TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. | Int Immunopharmacol | 2022 | 34906856 | PubTator, text mining | PubMed |
| Feedback regulation of antioxidant transcription factor NFE2L1 and immunostimulatory factor 41BBL mediates the crosstalk between oxidative stress and tumor immunity. | Mol Immunol | 2022 | 34902807 | PubTator, text mining | PubMed |
| Proteomic analysis of serum in workers exposed to diesel engine exhaust. | Environ Mol Mutagen | 2022 | 34894159 | PubTator, text mining | PubMed |
| PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress. | Cancer Immunol Res | 2022 | 34853030 | PubTator, text mining | PubMed |
| Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens. | Cancer Immunol Immunother | 2022 | 34821951 | PubTator, text mining | PubMed |
| CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury. | J Clin Invest | 2022 | 34813503 | PubTator, text mining | PubMed |
| Transcriptomic profiling reveals gene expression in human peripheral blood after exposure to low-dose ionizing radiation. | J Radiat Res | 2022 | 34788452 | PubTator, text mining | PubMed |
| Sensitive identification of neoantigens and cognate TCRs in human solid tumors. | Nat Biotechnol | 2022 | 34782741 | PubTator, text mining | PubMed |
| SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity. | Cell Immunol | 2022 | 34773897 | PubTator, text mining | PubMed |
| Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia. | Blood | 2022 | 34699594 | PubTator, text mining | PubMed |
| Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. | Cancer Immunol Immunother | 2022 | 34661709 | PubTator, text mining | PubMed |
| Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity. | Cell Mol Immunol | 2022 | 34580436 | PubTator, text mining | PubMed |
| Human vaccines & immunotherapeutics news: July 2020. | Hum Vaccin Immunother | 2022 | 34506265 | PubTator, text mining | PubMed |
| The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease. | J Crohns Colitis | 2022 | 34491321 | PubTator, text mining | PubMed |
| Unleashing the power of NK cells in anticancer immunotherapy. | J Mol Med (Berl) | 2022 | 34374809 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=56